EphA3 antibody Polyclonal Antibodies Primary antibodies
- Known as:
- EphA3 (anti-) Polyclonal Antibodies Primary antibodies
- Catalog number:
- orb100577
- Product Quantity:
- 100
- Category:
- -
- Supplier:
- Biorb
- Gene target:
- EphA3 antibody Polyclonal Antibodies Primary antibodies
Related genes to: EphA3 antibody Polyclonal Antibodies Primary antibodies
- Gene:
- EPHA3 NIH gene
- Name:
- EPH receptor A3
- Previous symbol:
- ETK, ETK1, TYRO4
- Synonyms:
- HEK, HEK4
- Chromosome:
- 3p11.1
- Locus Type:
- gene with protein product
- Date approved:
- 1993-06-23
- Date modifiied:
- 2016-10-05
Related products to: EphA3 antibody Polyclonal Antibodies Primary antibodies
Related articles to: EphA3 antibody Polyclonal Antibodies Primary antibodies
- Investigating the genetic underpinnings of functional brain connectivity is essential to understand how genetic variation influences brain health and disease. Here, a mass-univariate approach was adopted to study the genetic architecture of functional brain circuitry (N = 28,159 subjects) with high spatial resolution (82 brain regions). Common genetic variants explained individual differences in 33% of all 3321 inter-regional functional pathways with 72 significant associations reflecting widespread, pleiotropic effects across the connectome. These associations were mapped to five genes-PAX8, EphA3, SLC39A12, THBS1 and APOE-with known associations with brain phenotypes and which converged in biological processes related to neurodevelopment and cardiovascular and cognitive traits (enrichment minimum p = 3.0 × 10 and p = 1.6 × 10, respectively). Our findings show that the genetic component of individual differences in functional brain connectivity is largely shared throughout the brain, highlighting the importance of genetic variation in large-scale brain organisation and its relationship with cognitive function and overall health. - Source: PubMed
Publication date: 2026/02/24
Maciel Bernardo de ApcSchipper MarijnRomero Catode Leeuw ChristiaanHelwegen KoenPosthuma DanielleSavage Jeanne Evan den Heuvel Martijn P - Enhancing growth traits is a key goal in sustainable meat goat production and is often regarded as a primary objective in breeding programmes for meat goats. In this study, whole genome low-depth sequencing data of 300 Longling yellow female goats were used to detect the genome-wide single-nucleotide polymorphisms (SNPs), and the genome-wide association study (GWAS) based on SNPs was performed for the BW, body height (BH), body length (BL), chest circumference (CC), chest depth (CD), chest width (CW), and cannon circumference (cc) at the ages of 3, 9, and 12 months. After genotype imputation and quality control, 6 153 300 SNPs were retained for further analysis. A total of 129 genome-wide significant SNPs were obtained, and these SNPs were annotated to 146 candidate genes associated with body size traits, such as MMP16, MECOM for BW; SCD5, LEF1 for BL; and PDE4D, KCND2 for BH. EPHA5 is pleiotropic, associated with BW, BL, BH, CC, and CW. Notably, ADAMTS3 was linked to CD, while GIGYF2 and DGKB were associated with cc. Functional analysis revealed that 13 candidate genes are implicated in pivotal biological processes, including extracellular matrix organisation and lipid metabolism. Notably, EPHA5, ROS1, and EPHA3 were significantly enriched in molecular functions related to growth factor receptor activity. These findings offer valuable genetic markers for genomic selection in goats, thereby providing resources for advancing precision breeding programmes. - Source: PubMed
Publication date: 2026/01/22
He X YWei Y SKuang J CLi Z FYu Z XWang X YDi RZhu C YChu M X - Endocrine-disrupting chemicals (EDCs) are prevalent in various aspects of daily life, impacting the homeostasis of physiological processes and potentially contributing to the pathogenesis of cancer. Bladder cancer (BLCA) is the most common malignancy of the urinary system and one of the most prevalent malignancies globally. Cellular senescence is increasingly recognized as a key factor in cancer development. However, research remains limited regarding how EDCs influence BLCA through senescence-related genes (SRGs). In this study, expression data and clinical information were sourced from the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. Senescence phenotype-related differentially expressed genes (DEGs) were identified. A senescence-related risk model was developed and validated by TCGA and GEO datasets. EDCs targeting DEGs, were extrapolated using the chemical toxicogenomic database (CTD). A Sankey diagram is employed to visualize the relationships between EDCs and key genes, identifying AKR1B1, EPHA3, IRF5, PGR, SREBF1 and TEAD4, as key factors in predicting cellular senescence in BLCA. Finally, molecular docking analysis was conducted to investigate the interaction between key genes and EDCs, thereby validating their feasibility. Our findings provide new insights into the role of SRGs in BLCA stratification and precision medicine. Furthermore, we elucidated the relationship between EDC-mediated cell SRGs and the pathogenesis of BLCA. - Source: PubMed
Publication date: 2026/02/07
Qin MaohuaXie GuofengXie HaimengLin BaishengDai ZiliCheng ZijinWang LiZhang JianWang Feixiang - Recurrent high-grade gliomas have a dismal prognosis. This review article aimed to explore and help answer the questions about which group of patients would benefit from chimeric antigen receptor therapy (CAR-T) cell therapy in this setting, the timing of intervention and the therapeutic efficacy. CAR-T cell therapy involves the extraction of T-cells from patients, genetic modification of these cells to express chimeric antigen receptors on their cell surface, which are selectively targeted towards tumour-expressed antigens and a procedure of immune-depletion followed by re-introducing these engineered CAR-T cells into the host via infusion. Gliomas, particularly glioblastoma, present unique challenges due to their immune-evasive nature, location within the central nervous system and antigenic heterogeneity. Thus, several potential antigenic targets are being explored for CAR-T cell therapy, including B7 homolog 3, Disiloganglioside, Eph-A2, Eph-A3, IL-13Ra2, HER2, EGFRvIII and Matrix metalloproteinase-2. - Source: PubMed
Publication date: 2025/09/30
Parekh DeevyashaliPatel Ansy HKhan AreebOlojakpoke ElohoKarpe AshayPeelay ZoyaPatil Vijay - SMARCA4 (BRG1)-deficient undifferentiated tumor is a rare and highly aggressive malignant tumor. Cases arising in the bladder are exceedingly rare, and their molecular pathogenesis remains poorly understood. Here, we present the first, to our knowledge, report of a case of bladder SMARCA4 (BRG1)-deficient undifferentiated tumor incorporating comprehensive genomic profiling. Ultra-deep sequencing analysis using a 601-gene panel targeting tumor molecular targeted therapy, immunotherapy, and hereditary susceptibility revealed a novel oncogenic nonsense mutation in the SMARCA4 gene (p.K867*), with a high mutant allele frequency of 71%. This mutation has not been previously reported in any tumor type. Meanwhile, loss of heterozygosity was also found in the SMARCA4 gene. Additionally, seven variants with potential clinical significance-TP53 (c.919 + 1G > A), TP53 (c.823dup), FGF19 amplification, FGF3 amplification, CCND1 amplification, FGF4 amplification, and STAG2 (c.289-2A > T)-and nine variants of uncertain clinical significance-BRIP1, EPHA3, FLT4, GLI1, KMT2C, KMT2D, LGMN, MGA, and RICTOR-were detected. This suggests that besides SMARCA4 deficiency, alterations in other genes may cooperatively contribute to the tumorigenesis of bladder undifferentiated tumors. These findings provide a reference for subsequent exploration of precise diagnostic and prognostic assessment and treatment strategies for this disease. - Source: PubMed
Publication date: 2026/01/20
Lu Xing-WangNing Chun-MengGao Bo